Hemangioblastoma
Hemangioblastoma is a benign WHO Grade I vascular tumour of the central nervous system, most commonly arising in the cerebellum, brainstem, and spinal cord. These tumours are composed of neoplastic stromal cells within a dense network of capillary-like vessels, accounting for 2 per cent of all intracranial tumours.
Understanding Hemangioblastoma
Hemangioblastomas occur sporadically in 75 per cent of cases and as part of von Hippel-Lindau (VHL) disease in the remaining 25 per cent. In VHL patients, hemangioblastomas are frequently multiple and recur throughout life, requiring a lifetime surveillance and treatment strategy. The tumours are highly vascular and frequently associated with peritumoural cysts or a large cyst with a small mural nodule. The cystic component often accounts for the majority of the mass effect, and symptoms arise from compression of adjacent neural structures or from hydrocephalus when the tumour blocks CSF pathways.
Complete microsurgical resection is curative for sporadic hemangioblastomas. For small, deep, or multiple lesions, Gamma Knife radiosurgery offers an excellent alternative with high tumour control rates. Istanbul provides access to expert neurosurgical care for both sporadic and VHL-associated hemangioblastomas at a fraction of Western costs.
Treatment Options for Hemangioblastoma
View All ProceduresSymptoms of Hemangioblastoma
Presenting symptoms depend on tumour location. Cerebellar hemangioblastomas produce headache, nausea, vomiting, gait ataxia, dysmetria, and nystagmus — classic posterior fossa symptoms often progressing over weeks to months as the associated cyst enlarges. Spinal hemangioblastomas cause back pain, sensory disturbance, weakness, and sphincter dysfunction corresponding to the level of involvement. Brainstem hemangioblastomas present with cranial nerve deficits, long tract signs, and potentially life-threatening respiratory compromise. In VHL patients, symptoms may be multifocal due to simultaneous lesions at multiple CNS levels, and the diagnosis is often already known from genetic screening.
Diagnostic Pathways
MRI with gadolinium is the imaging modality of choice. Hemangioblastomas appear as well-circumscribed, intensely enhancing mural nodules, frequently with a large non-enhancing peritumoural cyst. The cyst wall does not typically enhance, distinguishing hemangioblastomas from other cystic tumours. Digital subtraction angiography demonstrates the characteristic dense, well-circumscribed tumour blush with prominent feeding arteries and early draining veins. Screening for VHL disease is mandatory in all patients with hemangioblastoma — including fundoscopic examination for retinal haemangioblastomas, abdominal imaging for renal cell carcinoma and phaeochromocytoma, and genetic testing for VHL germline mutations.
Advanced Treatment Options at Vellum Select
Microsurgical Resection
Complete microsurgical resection is curative for sporadic hemangioblastomas. The tumour is well-circumscribed and does not invade surrounding brain, allowing for a clean plane of dissection. Pre-operative embolisation may be used for large vascular tumours to reduce intraoperative blood loss.
Gamma Knife Radiosurgery
For small solid hemangioblastomas (under 3 cm), deep-seated lesions, residual tumour after surgery, or multiple VHL-associated lesions, Gamma Knife Radiosurgery in Turkey achieves tumour control rates of 85–90 per cent at five years. The non-invasive approach is particularly valuable in VHL patients who face a lifetime of multiple treatments.
To discuss your hemangioblastoma diagnosis with Prof. Dr. Türker Kılıç, view his profile or contact Vellum Select to arrange a consultation.
